Graft vs Host Disease (Graft-Versus-Host Disease) Summary

Networked: 11535 relevant articles (613 outcomes, 744 trials/studies) for this Disease

Key Drugs and Agents for Graft vs Host Disease

1. Cyclosporine (Ciclosporin) : 57 outcomes 65 studies in 1170 results : FDA 20 Generic
   
2. Methotrexate (Mexate) : 29 outcomes 43 studies in 722 results : FDA 8 Generic
   
3. Tacrolimus (Prograf) : 24 outcomes 25 studies in 319 results : FDA 7 Generic
   
4. Cyclophosphamide (Cytoxan) : 13 outcomes 9 studies in 176 results : FDA 10 Generic
   
5. Thalidomide (Thalomid) : 13 outcomes 7 studies in 71 results : FDA 2
   
6. Antigens : 11 outcomes 22 studies in 450 results : IBA
   
7. alemtuzumab (Campath) : 11 outcomes 8 studies in 87 results : FDA 2
   
8. mycophenolate mofetil (Cellcept) : 11 outcomes 6 studies in 191 results : FDA 24 Generic
   
9. Antilymphocyte Serum (Anti-Thymocyte Globulin) : 9 outcomes 13 studies in 218 results : IBA
   
10. rituximab (Mabthera) : 9 outcomes 7 studies in 47 results : FDA 3
    

Diseases Related to Graft vs Host Disease

1. Leukemia
2. Infection
3. Neoplasms (Cancer)
4. Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
5. Autoimmune Diseases (Autoimmune Disease)

Key Therapies for Graft vs Host Disease

1. Transplants (Transplant) : 136 outcomes 155 studies in 2869 results
   
2. Transplantation (Transplant Recipients) : 89 outcomes 102 studies in 1745 results
   
3. Bone Marrow Transplantation (Transplantation, Bone Marrow) : 65 outcomes 115 studies in 1882 results
   
4. Hematopoietic Stem Cell Transplantation : 43 outcomes 75 studies in 1046 results
   
5. Stem Cell Transplantation : 42 outcomes 45 studies in 861 results